Clinical Trials Logo

Clinical Trial Summary

This prospective, randomized, controlled, multi-center clinical trial will evaluate the effect and security of steroids therapy for patients of IgA nephropathy with active pathological changes,including crescents,necrosis and microthrombus.


Clinical Trial Description

It has been reported that for urinary protein excretion that is persistently more than 1g/24h and eGFR>50ml/min/1.73m2 in IgA nephropathy(IgAN), the KDIGO guidelines suggest a 6-month course of glucocorticoids. The famous study by Pozzi C has proved that for patients of IgAN with proteinuria of 1.0-3.5g/24h and serum creatinine concentrations of 133 umol/L or less, a 6-month course of steroid treatment(1g/d methylprednisolone intravenously for 3 consecutive days,with the course repeated 2 months and 4 months later,then oral prednisone 0.5mg/kg/d on alternate days for 6 months) could significantly reduce proteinuria and protect against renal function deterioration in IgAN. Furthermore, as we know, active pathological changes in IgAN,including crescents,necrosis and microthrombus,which may turn fibrosis after three months would effect the prognosis.This will be a prospective, randomized, controlled, multi-center study. Patients in treatment group will receive 0.5g/d methylprednisolone intravenously for 3 consecutive days in the 1st-2nd-3rd month ,then oral methylprednisolone 0.4mg/kg/d on consecutive days Patients in control group will receive 0.5g/d methylprednisolone intravenously for 3 consecutive days in the 1st-3rd-5th month ,then oral methylprednisolone 0.4mg/kg/d on consecutive days. After followed-up for 6 months, the curative effect of steroid therapy on proteinuria and the progression of IgAN will be evaluated. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT02160132
Study type Interventional
Source Sun Yat-sen University
Contact Zongpei Jiang, M.D. & Ph.D.
Phone 8620-38379727
Email jx.home@medmail.com.cn
Status Recruiting
Phase Phase 2
Start date June 2014
Completion date December 2016

See also
  Status Clinical Trial Phase
Terminated NCT03841448 - A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN) Phase 2
Recruiting NCT04020328 - Leflunomide Plus Low Dose Corticosteroid in Immunoglobulin A (IgA) Nephropathy With Renal Insufficiency Phase 4
Completed NCT02232776 - Efficacy and Safety of Losartan in Children With Ig A Nephropathy Phase 3
Recruiting NCT04092491 - Study of the IgA Repertoire During IgA Deposition Nephropathy.
Not yet recruiting NCT05797051 - Application of Hyperspectral Imaging in the Diagnosis of Glomerular Diseases
Recruiting NCT05791162 - Interest of Follicular Helper Lymphocytes / Regulatory Follicular Helper Lymphocytes Ratio in IgA Nephropathy N/A
Terminated NCT02647255 - Trial of Plasma Exchange for Severe Crescentic IgA Nephropathy Phase 2/Phase 3
Recruiting NCT01184599 - A Prospective Study of the Kidney Protective Effect of Aliskiren in Hypertensive Patients With IgA Nephropathy Phase 4
Active, not recruiting NCT00378443 - ACEi/ARB Alone Versus ACEi/ARB Plus Steroids in the Treatment of Primary IgA Nephropathy, a RCT N/A
Completed NCT00396721 - Sirolimus Therapy for Poor Prognosis Immunoglobulin A Nephropathy Phase 2
Recruiting NCT01802034 - Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID)
Recruiting NCT05510323 - Efficacy of Immunosuppressive Therapy for IgA Nephropathy With Stage 3 or 4 CKD Phase 3
Completed NCT00446251 - Effects of Rituximab and Mycophenolate Mofetil (MMF) on Highly Sensitized Patients Awaiting Renal Transplant Phase 2
Active, not recruiting NCT04663204 - A Study of the Safety and Activity of Sparsentan for the Treatment of Incident Patients With Immunoglobulin A Nephropathy Phase 2
Completed NCT00521508 - Role of Regulatory T Cells in Pathogenesis of Primary IgA Nephropathy N/A
Completed NCT00446459 - Effects of Mycophenolate Mofetil (MMF) On Anti-HLA (Human Leukocyte Antigen)Antibody Levels In Patients Awaiting Cadaveric Renal Transplant. Phase 2